Global Information
회사소개 | 문의 | 비교리스트

CountryFocus : 싱가포르의 의료, 규제, 의료비 상환 제도 상황

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore

리서치사 GlobalData
발행일 2020년 04월 상품 코드 321243
페이지 정보 영문 140 Pages
가격
US $ 1,995 ₩ 2,390,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,990 ₩ 4,780,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,985 ₩ 7,171,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


CountryFocus : 싱가포르의 의료, 규제, 의료비 상환 제도 상황 CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore
발행일 : 2020년 04월 페이지 정보 : 영문 140 Pages

싱가포르의 인구는 기대수명 개선 등의 영향에 의해 2008년에는 480만명, 2013년에는 540만명으로 계속 증가하고 있습니다. 이에 따라 의약품 시장도 2008년에는 48,900만 달러, 2013년에는 76,100만 달러, 연평균 성장률(CAGR)은 9.3%로 확대 경향이 계속되고 있습니다. 또한 2014년의 시장규모는 77,600만 달러, 2020년에는 87,300만 달러, 2014-2020년간 CAGR은 2.0%로 추산됩니다. 한편, 의료 기술 부문의 생산액은 2011년에는 43억 싱가포르 달러(34억 달러)에 달했으며, 2015년에는 50억 싱가포르 달러(40억 달러)로 확대될 전망입니다. 정부의 적극적인 지원책 및 대학에서의 활발한 연구 활동이 의료 관련 시장의 플러스 성장에 기여하고 있습니다.

싱가포르 의료 관련 시장의 동향, 의료비 상환 제도 및 기타 관련 규제·제도에 대해 분석했으머, 의약품 산업·의료기기 산업의 전체적 구조·동향, 의료비 상환 제도 및 주변 보험 시장의 동향, 의료 규제기관의 구조 및 각종 규제 개요, 싱가포르 경제·사회에 관한 거시적 지표(의료 인프라 등), 향후 시장 기회와 과제 등의 정보를 정리하여 전해드립니다.

제1장 목차

제2장 서론

제3장 의약품·의료기기 시장의 개요

  • 의약품 시장
    • 시장 개요
    • 의약품 수출입
    • 공급 채널
    • 시장 분류
    • 주요 질환 분야
    • 주요 진출 기업
  • 의료기기 시장
    • 시장 개요
  • 시장 촉진요인과 장벽
    • 촉진요인
    • 진출 장벽

제4장 시장 접근

  • 의료비 상환·보험료 지불자의 상황
    • 의료 제도 개요
    • 의료비 상환 프로세스
    • 보험 사업자 개요
    • 의료비 지출에 대한 환자 부담의 비율
    • 의료 서비스의 가격 동향
    • 약가 정책
  • 규제 상황
    • 규제기관 개요
    • 의약품의 시판 승인 과정
    • 새로운 의료기기의 승인 과정
    • 의료기기의 신제품 인증 과정
    • 수출입
    • 지적소유권
    • 임상시험 관련 규제
    • 의약품 광고에 관한 규제
    • 약국 관련 규제
    • 라벨링·포장에 관한 규제

제5장 국가별 분석

  • 정치적 환경
    • 정치적 구조
    • 현재의 정치적 환경에 관한 분석
    • 의료 정책 구상
  • 경제정세
  • 경제지표
    • 국내총생산(GDP)
    • 국민총소득
    • 인플레이션
    • 환율
    • 외국인직접투자
    • 외화 준비금
    • 무역수지
    • 정부 구조 균형
    • 국채 발행 총액
    • 주요 산업
  • 인구통계
    • 인구
    • 교육 및 문맹퇴치율
    • 취업 상황
    • 질환 부담
  • 의료 인프라
    • 의료 설비
    • 의료 파라미터
    • 환경위생
    • 의료 인력
  • 의료비
    • 개요
    • 공공/민간 부문의 점유율
    • 의료비 지출의 주요 내용
    • 의약품 연구개발에 대한 지출액
  • 산업단체
  • 무역박람회

제6장 시장 기회 및 과제

  • 시장 기회
  • 과제

제7장 부록

도표

KSA 15.01.07

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1: Major Therapeutic Areas, Singapore, 2020
  • Table 2: COVID-19 Indicators (Number of cases), Global and Singapore, 2020
  • Table 3: COVID-19 Clinical Trials, Singapore, 2020
  • Table 4: COVID-19 Test Kits available for Diagnosis of COVID-19

List of Figures

  • Figure 1: Pharmaceutical Market, Singapore, Revenue ($B), 2012-2019
  • Figure 2: Medical Devices Market, Singapore, Revenue ($B), 2016-2019
  • Figure 3: Healthcare Startups in Singapore, Singapore, 2020
  • Figure 4: Number of Deals (2019-2020)
  • Figure 5: 2019-2020 Deal Overview by Region
  • Figure 6: Country Profile, Singapore, 2019
  • Figure 7: Pharmaceutical Market, Singapore, Revenue ($B), 2012-2019
  • Figure 8: Pharmaceutical Market, Singapore, Revenue Forecast ($B), 2020-2024
  • Figure 9: Pharmaceutical Market, Singapore, Pharmaceutical Exports ($B), 2012-2019
  • Figure 10: Pharmaceutical Market, Singapore, Top Export Partners, 2019
  • Figure 11: Pharmaceutical Market, Singapore, Pharmaceutical Imports, ($B), 2012-2019
  • Figure 12: Pharmaceutical Market, Singapore, Top Import Partners, 2019
  • Figure 13: Pharmaceutical Market, Supply Chain, Singapore, 2020
  • Figure 14: Growth of Biopharmaceutical Sector, Singapore, 2020
  • Figure 15: List of Registered Biosimilars, Singapore, 2009-2019
  • Figure 16: OTC Market, Singapore, Revenue ($B), 2012-2018
  • Figure 17: OTC Market by Drug Category, Singapore, Revenue ($M), 2018
  • Figure 18: Major Therapeutic Areas, Singapore, 2020
  • Figure 19: COVID-19 (Number of cases), Singapore, 2020
  • Figure 20: COVID-19 (Number of deaths), Singapore, 2020
  • Figure 21: Medical Devices Market, Singapore, Revenue ($B), 2016-2019
  • Figure 22: Medical Devices Market, Singapore, Revenue by Segment ($M), 2018
  • Figure 23: Medical Devices Market, Singapore, Revenue ($B) of Major Companies, 2019
  • Figure 24: Deal Value and Deal Count, Pharmaceutical Market, Singapore, 2019-2020
  • Figure 25: Deal Value and Deal Count Quarterly, Pharmaceutical Market, Singapore, 2019
  • Figure 26: Deal Value and Deal Count Sub-types, Pharmaceutical Market, Singapore, 2019-2020
  • Figure 27: Pharmaceutical Market, Singapore, Top Five Therapy Areas by Deal Value ($M), 2019-2020
  • Figure 28: Pharmaceutical Market, Singapore, Venture Capital Financing Deals by Therapy Area, 2019-2020
  • Figure 29: Pharmaceutical Market, Singapore, Top Five Therapy Areas by Deal Number, 2019-2020
  • Figure 30: Medical Devices Market, Singapore, M&A Deals by Therapy Area, 2019-2020
  • Figure 31: Deal Value, HealthTech, Singapore, 2019-2020
  • Figure 32: Deal Count, HealthTech, Singapore, 2019-2020
  • Figure 33: Overview of Healthcare System, Singapore, 2020
  • Figure 34: MOH Organizational Structure, Singapore, 2020
  • Figure 35: Standard Drug List Formation, Singapore
  • Figure 36: Overview of Expedited Evaluation Process, Singapore, 2020
  • Figure 37: Overview of Full Evaluation Process, Singapore, 2020
  • Figure 38: Healthcare Financing, Singapore, 2020
  • Figure 39: Integrated Shield Plans (IPs), Singapore, 2020
  • Figure 40: OOP Expenditure (% of total expenditure on health), Singapore, 2012-2016
  • Figure 41: Annual Rate of Change (%), Health Price Index, Singapore, 2012-2019
  • Figure 42: HSA Organizational Structure, Singapore, 2020
  • Figure 43: Drug Registration Process, Singapore, 2020
  • Figure 44: Medical Devices Registration, Singapore, 2020
  • Figure 45: Patent Approval Process, Singapore, 2020
  • Figure 46: Trademark Approval Process, Singapore, 2020
  • Figure 47: Pharmaceutical Clinical Trials Count by Trial Status, Singapore, 2019-2020
  • Figure 48: Pharmaceutical Clinical Trials Count by Phase, Singapore, 2019-2020
  • Figure 49: Pharmaceutical Clinical Trials Count by Indication, Singapore, 2019-2020
  • Figure 50: Top Five Pharmaceutical Clinical Trials Sponsors by Count, Singapore, 2019-2020
  • Figure 51: CTA-CTN Regulatory Roadmap, Singapore, 2020
  • Figure 52: CTC Regulatory Roadmap, Singapore, 2020
  • Figure 53: Hospitals by Type (number), Singapore, 2012-2018
  • Figure 54: Hospitals (number), Singapore, 2012-2018
  • Figure 55: Acute Hospital Beds (number), Singapore, 2012-2018
  • Figure 56: Psychiatric Hospital Beds (number), Singapore, 2012-2018
  • Figure 57: Community Hospital Beds (number), Singapore, 2012-2018

GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Singapore. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts.

Singapore's pharmaceutical market value in terms of US dollars was worth $0.7B in 2012, which increased at a CAGR of 7.4% to $1.0B in 2017. The increasing pharmaceutical market value is attributed to high life expectancy, expansion of healthcare system, developed medical infrastructure, improved patient access, and an increasing number of foreign pharmaceutical companies with a regional headquarters. Singapore's medical devices market was valued at $2.55B in 2016, and was estimated to be $2.50B in 2019. The rapidly aging population drives demand for innovative medical technologies and therapeutic devices.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Singapore, and includes -

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Roche, Novartis, Merck, GlaxoSmithKline, and Haw Par
  • Profiles and SWOT analyses of the major players in the medical device market: Medtronic, Becton Dickinson, Baxter International, Zimmer Biomet, and Edwards Lifesciences
  • An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in healthcare market, HealthTech landscape, reimbursement and regulatory landscape, with analysis covering details of the country's healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
  • Detailed analysis of the country's healthcare policy highlights, demographics, healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Singaporean healthcare market

Reasons to Buy

This report will enhance your decision-making capability by allowing you to -

  • Develop business strategies by understanding the trends shaping and driving Singapore's healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Singapore's healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors' performance
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

Table of Contents

  • 1.1 List of Figures
  • 1.2 List of Tables

2 Executive Summary

  • 2.1 Executive Summary - Overview
  • 2.2 Key Highlights
  • 2.3 Key Highlights: Healthcare Start-Ups in Singapore
  • 2.4 Key Events: Singapore Healthcare History, 2002-2020
  • 2.5 Key Events: Singapore Pharmaceutical Market
  • 2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2019-2020
  • 2.7 Key Events: Mergers and Acquisitions
  • 2.8 Country Profile, Singapore, 2019

3 Overview of Pharmaceutical Market

  • 3.1 Pharmaceutical Market - Overview
  • 3.2 Pharmaceutical Market - Exports
  • 3.3 Pharmaceutical Market - Imports
  • 3.4 Pharmaceutical Market - Supply Channels, Singapore
  • 3.5 Pharmaceutical Market - Market Segments
  • 3.6 COVID-19 Epidemiology, Singapore
  • 3.7 COVID-19 Impact and Developments in Healthcare Market, Singapore
  • 3.8 Pharmaceutical Market - Major Players

4 Overview of Medical Devices Market

  • 4.1 Medical Device Market - Overview
  • 4.2 Medical Device Market - Major Segments
  • 4.3 Medical Device Market - Major Players

5 Pharmaceutical and Medical Device Market - Drivers and Barriers

  • 5.1 Drivers
  • 5.2 Barriers

6 Deal analysis

  • 6.1 Deal Analysis: M&A, VC, and PE Deals, Pharmaceutical Market, Singapore 2019-2020

7 HealthTech Landscape

  • 7.1 HealthTech Landscape
    • 7.1.1 HealthTech Deals Landscape, Singapore
  • 7.2 Key HealthTech Deals, Singapore
  • 7.3 Adoption of Technology in Healthcare, Singapore
  • 7.4 Key Developments: Technology in Healthcare, Singapore
  • 7.5 Regulatory Scenario Covering Use of Technology in Healthcare
  • 7.6 HealthTech Landscape- Singapore- Benefits and Risks

8 Market Access

  • 8.1 Overview of Healthcare System, Singapore
  • 8.2 Reimbursement of Medicinal Products, Singapore
  • 8.3 Overview of Public and Private Insurance Providers, Singapore
  • 8.4 Healthcare Spending and Health Price Index, Singapore
  • 8.5 Pricing Policies, Singapore
  • 8.3 Regulatory Landscape, Singapore
    • 8.3.1 Market Authorization for Pharmaceutical Drugs, Singapore
    • 8.3.2 Market Authorization for Medical Devices, Singapore
    • 8.3.3 Intellectual Property Rights, Patent, Singapore
    • 8.3.4 Intellectual Property Rights, Trademark, Singapore
    • 8.3.5 Pharmaceutical Clinical Trials Landscape, Singapore
    • 8.3.6 Clinical Trial Regulations, Singapore
    • 8.3.7 Exports and Imports Regulation, Singapore
    • 8.3.8 Pharmacy Regulation, Singapore
    • 8.3.9 Pharmaceutical Advertising Regulations, Singapore
    • 8.3.10 Labeling and Packaging Regulations, Singapore

9 Country Healthcare Landscape

  • 9.1 Singapore Healthcare Policy Highlights
  • 9.2 Healthcare Facilities, Singapore
  • 9.3 Healthcare Parameters, Singapore
  • 9.4 Life Expectancy and Immunization Rate, Singapore
  • 9.5 Environmental Health, Singapore
  • 9.6 Healthcare Personnel, Singapore
  • 9.7 Disease Burden, Singapore
  • 9.8 Healthcare Expenditure

10 Trade Associations, Singapore

11 Trade Fairs, Singapore

12 Opportunities and Challenges

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Coverage
    • 13.1.2 Secondary Research
    • 13.1.3 Forecasts
    • 13.1.4 Expert Panel
  • 13.2 Bibliography
  • 13.3 Contact Us
  • 13.4 Disclaimer
Back to Top
전화 문의
F A Q